other material
confidence high
sentiment positive
materiality 0.85
Adicet Bio ADI-001 Phase 1 shows 71% ORR; pivots to Phase 2 in 1H24
Adicet Bio, Inc.
- ADI-001 achieved 71% ORR & 63% CR across doses in heavily pre-treated NHL (median 4 prior lines; 50% post-CAR T).
- At RP2D (1B cells), CR rate 63%, 6-month CR rate 25%; in post-CAR T patients CR rate 67% (6-month CR 33%).
- No GvHD; only 1 Grade 3+ CRS and 1 Grade 3+ ICANS among 24 safety-evaluable patients.
- FDA Type B meeting completed; plan to start potentially pivotal Phase 2 in post-CAR T LBCL in 1H 2024.
- ADI-001 persistence at RP2D (Cmax 483 cells/µL day 9) exceeded approved autologous CD19 CAR T.